• 3 - 5 This report by the Spanish Lymphoma Group (GELTAMO) aims to provide useful guidelines and recommendations for the prevention, diagnosis, and treatment of central nervous system diffuse large B-cell lymphoma patients with, or at risk of, leptomeningeal and/or brain parenchyma lymphoma relapse. (haematologica.org)
  • Several factors hinder the identification of risk factors for central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL), including the retrospective nature of most studies, the relatively low frequency of CNS relapse in DLBCL, and the heterogeneity of CNS prophylaxis methods used in these studies. (haematologica.org)
  • A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. (lookformedical.com)
  • A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes. (lookformedical.com)
  • Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. (lookformedical.com)
  • Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of care for patients with advanced indolent lymphoma, and for elderly patients with mantle-cell lymphoma. (nih.gov)
  • Patients aged 18 years or older with a WHO performance status of 2 or less were eligible if they had newly diagnosed stage III or IV indolent or mantle-cell lymphoma. (nih.gov)
  • 1. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. (nih.gov)
  • 2. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. (nih.gov)
  • 3. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. (nih.gov)
  • 4. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). (nih.gov)
  • 6. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. (nih.gov)
  • 7. Treatment of older patients with mantle-cell lymphoma. (nih.gov)
  • 8. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. (nih.gov)
  • 9. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). (nih.gov)
  • 10. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. (nih.gov)
  • 12. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. (nih.gov)
  • 2012 Wiley Periodicals, Inc. consecutive consensus conferences, the issues were analyzed and dis- Follicular cell lymphoma (FL) is a frequent disorder for cussed according to the nominal group technique, as previously described [5]. (health-articles.net)
  • In the 2008 WHO classification, grade 3b FL were separated and are universally treated as diffuse large reported the clinical outcomes in patients in which the ther- B-cell lymphoma (DLBCL) [2]. (health-articles.net)
  • A new approach that avoids chemotherapy and instead uses a combination of lenalidomide ( Revlimid , Celgene Corporation) plus rituximab ( Rituxan , Genentech, Inc/Biogen Idec Limited) was effective and safe when used as a first-line therapy for mantle cell lymphoma. (medscape.com)
  • Although there is no set standard for first-line therapy in mantle cell lymphoma, it usually includes cytotoxic chemotherapy. (medscape.com)
  • Given that the approach to mantle cell lymphoma treatment is highly variable and decisions are made with consideration of balancing efficacy and toxicity, the lenalidomide plus rituximab regimen represents a useful option to consider for some patients, particularly those who wish to avoid or cannot tolerate more intensive chemotherapy-based treatment," he told Medscape Medical News . (medscape.com)
  • Lenalidomide, a second-generation immunomodulatory compound, and rituximab, an anti-CD20 antibody, are both active in patients with recurrent mantle cell lymphoma. (medscape.com)
  • First-line treatment of mantle cell lymphoma varies, but it generally involves intensive approaches, including high-dose chemotherapy and hematopoietic-cell transplant, note the authors. (medscape.com)
  • Lenalidomide is approved for use in recurrent mantle cell lymphoma, he explained, and there are good data that suggest that lenalidomide combined with rituximab is more effective than the agent used alone. (medscape.com)
  • Relapses in mantle cell lymphoma generally occur in the range of 3 to 4 years, Dr Kahl pointed out. (medscape.com)
  • Dr Kahl did note that there is not one standard of care for frontline treatment of mantle cell lymphoma, so it is possible that some physicians may be interested in trying this regimen for certain patients. (medscape.com)
  • We compared bendamustine plus rituximab with CHOP plus rituximab (R-CHOP) as first-line treatment for patients with indolent and mantle-cell lymphomas. (nih.gov)
  • We feel that further study of this approach in larger trials will allow a better assessment of its value relative to other mantle cell leukemia regimens. (medscape.com)
  • A rule of thumb is that patients younger than 65 in the US will most likely receive more intensive regimens and stem cell transplantation, and those that are older, less intensive chemotherapy. (medscape.com)
  • High dose chemotherapy followed by hematopoietic stem cell transplant wasrecommended for young fit patients who achieve a response after salvage chemoimmunotherapy. (health-articles.net)
  • For patients, their quality of life was preserved or improved, and that's a huge step up from regular chemotherapy," said lead author Jia Ruan, MD, an associate professor of clinical medicine at Weill Cornell Medicine, New York City. (medscape.com)
  • Most patients receive some type of chemotherapy regimen first line. (medscape.com)